An optimized DHPLC protocol for molecular testing of the EXT1 and EXT2 genes in hereditary multiple osteochondromas

Clinical Genetics

Volumn 68, Issue 6, 2005, Pages 542-547

  Wuyts, Wim ^a,b   Radersma, R ^b   Storm, K ^b   Vits, L ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

DHPLC; EXT; Heparan sulfate; Multiple exostoses; Osteochondroma

Indexed keywords

PROTEIN EXT1; PROTEIN EXT2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; EXON; GENE MUTATION; GENETIC CODE; GENETIC SCREENING; HEREDITARY MULTIPLE EXOSTOSIS; HUMAN; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; VALIDATION PROCESS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; EXOSTOSES, MULTIPLE HEREDITARY; GENETIC SCREENING; HUMANS; N-ACETYLGLUCOSAMINYLTRANSFERASES; SEQUENCE ANALYSIS, DNA;

EID: 28644446964     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2005.00538.x     Document Type: Article

References (24)

1. Solomon L. Hereditary multiple exostosis. J Bone Joint Surg Br 1963: 45: 292-304.
2. Hennekam RCM. Hereditary multiple exostoses. J Med Genet 1991: 28: 262-266.
3. Schmale GA, Conrad EU, Raskind WH. The natural history of hereditary multiple exostoses. J Bone Joint Surg Br 1994: 76: 986-992.
4. Ahn J, Lüdecke H, Lindow S et al. Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1). Nature Genet 1995: 11: 137-143.
5. Stickens D, Clines G, Burbee D et al. The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes. Nat Genet 1996: 14: 25-32.
6. Wuyts W, Van Hul W, Wauters J et al. Positional cloning of a gene involved in hereditary multiple exostoses. Hum Mol Genet 1996: 5: 1547-1557.
7. Wise CA, Clines GA, Massa H et al. Identification and localization of the gene for EXTL, a third member of the multiple exostoses gene family. Genome Res 1997: 7: 10-16.
8. Wuyts W, Van Hul W, Hendrickx J et al. Identification and characterization of a novel member of the EXT gene family, EXTL2. Eur J Hum Genet 1997: 5: 382-389.
9. Van Hul W, Wuyts W, Hendrickx J et al. Identification of a third EXT-like gene (EXTL3) belonging to the EXT gene family. Genomics 1998: 47: 230-237.
10. Lind T, Tufaro F, McCormick C et al. The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem 1998: 273: 26265-26268.
11. McCormick C, Leduc Y, Martindale D et al. The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet 1998: 19: 158-161.
12. Kim BT, Kitagawa H, Tamura J et al. Human tumor suppressor EXT gene family members EXTL1 and EXTL3 encode alpha 1,4-N-acetylglucosaminyltransferases that likely are involved in heparan sulfate/heparin biosynthesis. Proc Natl Acad Sci USA 2001: 98: 7176-7181.
13. Kitagawa H, Shimakawa H, Sugahara K. The tumor suppressor EXT-like gene EXTL2 encodes an alpha 1,4-N-acetylhexosaminyltransferase that transfers N-acetylgalactosamine and N-acetylglucosamine to the common glycosaminoglycan-protein linkage region - The key enzyme for the chain initiation of heparan sulfate. J Biol Chem 1999: 274: 13933-13937.
14. McCormick C, Duncan G, Goutsos KT et al. The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the golgi apparatus and catalyzes the synthesis of heparan sulfate. Proc Natl Acad Sci USA 2000: 97: 668-673.
15. Koziel L, Kunath M, Kelly OG et al. Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. Dev Cell 2004: 6: 801-813.
16. Wuyts W, Van Hul W. Molecular basis of multiple exostoses: mutations in the EXT1 and EXT2 genes. Hum Mutat 2000: 15: 220-227.
17. Wuyts W, Van Hul W, De Boulle K et al. Mutations in the EXT1 and EXT2 genes in hereditary multiple exostoses. Am J Hum Genet 1998: 62: 346-354.
18. Vink GR, White SJ, Gabelic S et al. Mutation screening of EXT1 and EXT2 by direct sequence analysis and MLPA in patients with multiple osteochondromas: splice site mutations and exonic deletions account for more than half of the mutations. Eur J Hum Genet 2005: 13: 470-474.
19. White SJ, Vink GR, Kriek M et al. Two-color multiplex ligation-dependent probe amplification: detecting genomic rearrangements in hereditary multiple exostoses. Hum Mutat 2004: 24: 86-92.
20. Porter DE, Lonie L, Fraser M et al. Severity of disease and risk of malignant change in hereditary multiple exostoses. A genotype-phenotype study. J Bone Joint Sing Br 2004: 86: 1041-1046.
21. Francannet C, Cohen-Tanugi A, Le MM et al. Genotype-phenotype correlation in hereditary multiple exostoses. J Med Genet 2001: 38: 430-434.
22. Dobson-Stone C, Cox RD, Lonie L et al. Comparison of fluorescent single-strand conformation polymorphism analysis and denaturing high-performance liquid chromatography for detection of EXT1 and EXT2 mutations in hereditary multiple exostoses. Eur J Hum Genet 2000: 8: 24-32.
23. Philippe C, Porter DE, Emerton ME et al. Mutation screening of EXT1 and EXT2 genes in patients with hereditary multiple exostoses. Am J Hum Genet 1997: 61: 520-528.
24. Seki H, Kubota T, Ikegawa S et al. Mutation frequencies of EXT1 and EXT2 in 43 Japanese families with hereditary multiple exostoses. Am J Med Genet 2001: 99: 59-62.